Clinical Trial Update: A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial comparing efalizumab with cyclosporine as immunosuppression in de novo kidney transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• Raptiva (efalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Kidney Transplantation | Phase 2, Phase 3 | Status: WITHDRAWN